In the case of AZD6244 (selumetinib, another MEK inhibitor approved for neurofibromatosis type I and pediatric neurofibromas [41]), the largest performance was found for breast tumors (BA = 0.96 for 1 sensitive and 12 resistant cell lines), while performance was much more modest for other cancer types. This evidence concerns the gene MAP2K7 and neurofibroma.